相关实验视频

Updated: Jan 11, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

尼沃卢马布在转移性清细胞细胞癌中:来自NIVOREN GETUG-AFU 26第二阶段研究的综合生物标志物分析

Ronan Flippot¹, Yann-Alexandre Vano², Cécile Dalban³

¹Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.

European urology

|November 12, 2025

概括

像循环细胞因子 (IL-6,IL-8) 和瘤微环境特征这样的生物标志物可以预测转移性清细胞脏细胞癌 (ccRCC) 中nivolumab的有效性. 这些因素提供了关于ccRCC患者免疫治疗治疗结果的见解.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
翻译研究是翻译研究.

背景情况:

尼沃卢马布在耐火性转移性清细胞细胞癌 (ccRCC) 中显示出更好的生存率.
目前缺乏可靠的生物标志物来预测ccRCC中nivolumab活性.
血管内皮生长因子 (VEGF) 受体导向疗法是常见的一线治疗.

研究的目的:

为了确定基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因.
在现实环境中评估nivolumab的安全性和有效性.
将翻译研究与临床试验数据相结合.

主要方法:

一个现实世界的第二阶段临床试验,涉及720名用尼沃卢马布治疗的ccRCC患者.
通过免疫测试和基因表达造型评估候选组织和循环生物标志物的评估.
对瘤微环境特征的分析,包括免疫细胞透和基因表达特征.

主要成果:

尼沃卢马布的活性和安全性与关键试验数据一致.
在侵袭边缘的三级淋巴体结构,CD8+淋巴细胞和CD163+巨细胞与更长的无进展生存时间有边际关联.
瘤细胞上VEGF的高表达与较短的无进展和整体存活时间密切相关.
高瘤淋巴细胞透率和低中性粒细胞/细胞透率与改善的尼沃卢马布反应相关.
循环中升高的IL-6和IL-8水平独立地与较短的无进展和整体存活时间有关.

结论:

瘤微环境的免疫和血管性特征可以为ccRCC治疗nivolumab的结果提供信息.
循环细胞因子,特别是IL-6和IL-8,成为ccRCC中免疫治疗反应最有前途的预测因子.
这些生物标志物的进一步验证可以个性化ccRCC治疗策略.

关键词:

生物标志物生物标志物转移的清晰细胞脏细胞癌.分子分类的分子分类.尼沃卢马布的使用情况现实世界的研究研究.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...